Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting

Volumn 35, Issue , 2016, Pages e505-e514

  van Akkooi, Alexander C J ^a   Atkins, Michael B ^a   Agarwala, Sanjiv S ^a   Lorigan, Paul ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; HUMAN; IMMUNOLOGY; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RISK FACTOR; SURVIVAL ANALYSIS;

ANTIBODIES, MONOCLONAL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84993964920     PISSN: None     EISSN: 15488756     Source Type: Journal    
DOI: 10.14694/EDBK_159087     Document Type: Review

References (0)